EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 4.0

Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907)

Yuki Kojima, Keisuke Watanabe, Motoko Arakaki, Tadaaki Nishikawa, Yukari Hoshina, Kenta Anjo, Akihiro Hirakawa, Masahiko Ichimura, Makoto Endo, Ikuo Kudawara, Masanobu Takahashi, Genki Okumura und 5 weitere

European Journal of Cancer · 2026

DOI: 10.1016/j.ejca.2025.116104 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026. Verfasst von Yuki Kojima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Sarcoma, Alveolar Soft Part, Antibodies, Monoclonal, Humanized, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chugai Pharmaceutical.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sarcoma, Alveolar Soft PartAntibodies, Monoclonal, HumanizedImmune Checkpoint InhibitorsHumansAdultFemaleMaleYoung AdultMiddle AgedBiomarkers, TumorAdolescentExome Sequencing

Stichwörter der Autor:innen

alveolar soft part sarcomaatezolizumabbiomarkerimmune checkpoint inhibitoroutcome

Substanzen

Antibodies, Monoclonal, HumanizedatezolizumabBiomarkers, TumorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
  • Division of Cancer Immunology, National Cancer Center Research Institute, Tokyo, Japan.
  • Clinical Research Support Office, National Cancer Center Hospital, Tokyo, Japan.
  • Department of Clinical Biostatistics, Graduate School of Medical and Dental Sciences, Institute of Science, Tokyo, Japan.
  • Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan.
  • Department of Orthopaedic Surgery, Osaka National Hospital, Osaka, Japan.

Förderung

  • Chugai Pharmaceutical

Zitieren

APA

Kojima, Y., Watanabe, K., Arakaki, M., Nishikawa, T., Hoshina, Y., Anjo, K., Hirakawa, A., Ichimura, M., Endo, M., Kudawara, I., Takahashi, M., Okumura, G., Koyama, S., Yoshida, A., Shiraishi, K., Ichikawa, H., & Yonemori, K. (2026). Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907). European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.116104

Vancouver

Kojima Y, Watanabe K, Arakaki M, Nishikawa T, Hoshina Y, Anjo K, et al. Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907). European Journal of Cancer. 2026. doi:10.1016/j.ejca.2025.116104

BibTeX
@article{Kojima2026,
  author = {Kojima, Yuki and Watanabe, Keisuke and Arakaki, Motoko and Nishikawa, Tadaaki and Hoshina, Yukari and Anjo, Kenta and Hirakawa, Akihiro and Ichimura, Masahiko and Endo, Makoto and Kudawara, Ikuo and Takahashi, Masanobu and Okumura, Genki and Koyama, Shohei and Yoshida, Akihiko and Shiraishi, Kouya and Ichikawa, Hitoshi and Yonemori, Kan},
  title = {Clinical, immunological, and genomic findings of atezolizumab in advanced alveolar soft part sarcoma: A phase II trial (ALBERT trial/NCCH1907)},
  journal = {European Journal of Cancer},
  year = {2026},
  doi = {10.1016/j.ejca.2025.116104}
}
Kostenlos starten →